(Q38417643)

English

Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus

scientific article published on 26 February 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 September 2017

Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus (English)

1 reference

Europe PubMed Central

2 September 2017

gynecologic oncology

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

immunohistochemistry

1 reference

based on heuristic

inferred from title

author name string

Warner K Huh

1

1 reference

Europe PubMed Central

2 September 2017

Michael W Sill

2

1 reference

Europe PubMed Central

2 September 2017

Kathleen M Darcy

3

1 reference

Europe PubMed Central

2 September 2017

Kevin M Elias

4

1 reference

Europe PubMed Central

2 September 2017

James S Hoffman

5

1 reference

Europe PubMed Central

2 September 2017

John F Boggess

6

1 reference

Europe PubMed Central

2 September 2017

Ronald D Alvarez

7

1 reference

Europe PubMed Central

2 September 2017

Harry J Long

8

1 reference

Europe PubMed Central

2 September 2017

David M O'Malley

9

1 reference

Europe PubMed Central

2 September 2017

Michael J Birrer

10

1 reference

Europe PubMed Central

2 September 2017

language of work or name

0 references

publication date

26 February 2010

1 reference

Europe PubMed Central

2 September 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

2 September 2017

117

1 reference

Europe PubMed Central

2 September 2017

2

1 reference

Europe PubMed Central

2 September 2017

248-254

1 reference

Europe PubMed Central

2 September 2017

Retrospective analysis of 318 cases of uterine sarcoma

2 references

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of recurrence in malignant mixed müllerian tumor of the uterus

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Expression of c-kit in uterine carcinosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Immunohistochemical evaluation of KIT expression in sarcomas of the gynecologic region

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

PDGFR-alpha as a potential therapeutic target in uterine sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

C-kit protein expression in uterine and ovarian mesenchymal tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Different expression patterns of KIT, EGFR, and HER‐2 (c‐erbB‐2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Optimal flexible designs in phase II clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

On the Interpretation of χ 2 from Contingency Tables, and the Calculation of P

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

C-kit immunoreactivity in endometrial adenocarcinomas and its clinicopathologic significance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Prognostic value of KIT expression in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

KIT, PDGFRalpha and EGFR analysis in nephroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Resistance to c-KIT kinase inhibitors conferred by V654A mutation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.002

7 January 2021

Identifiers

10.1016/J.YGYNO.2010.01.002

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38417643&oldid=2166032599"